^
CANCER:

Brain Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
BRAF V600
Glioma
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
IDH wild-type
Glioblastoma
bevacizumab + retifanlimab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Glioblastoma
Byvasda (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Brain Cancer
lomustine
Sensitive
:
A1
No biomarker
Astrocytoma
everolimus
Sensitive
:
A1
No biomarker
Astrocytoma
carmustine
Sensitive
:
A1
No biomarker
Ependymoma
carmustine
Sensitive
:
A1
No biomarker
Medulloblastoma
carmustine
Sensitive
:
A1
No biomarker
Anaplastic Astrocytoma
temozolomide
Sensitive
:
A1
No biomarker
Glioblastoma
bevacizumab
Sensitive
:
A1
No biomarker
Glioma
carmustine
Sensitive
:
A1
No biomarker
Glioblastoma
temozolomide
Sensitive
:
A1
No biomarker
Glioblastoma
carmustine
Sensitive
:
A1
No biomarker
Glioblastoma
bevacizumab-bvzr
Sensitive
:
A1
No biomarker
Glioblastoma
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Glioblastoma
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Glioma
teserpaturev
Sensitive
:
A1
No biomarker
Glioblastoma
bevacizumab-maly
Sensitive
:
A1
IDH1 mutation
Astrocytoma
temozolomide
Sensitive
:
A2
BRAF V600E
Glioblastoma
trametinib + dabrafenib
Sensitive
:
A2
No biomarker
Glioblastoma
PCV
Sensitive
:
A2
No biomarker
Anaplastic Astrocytoma
PCV
Sensitive
:
A2
No biomarker
Glioma
PCV
Sensitive
:
A2
MGMT promoter methylation
Glioblastoma
temozolomide
Sensitive
:
A2
IDH2 mutation + Chr del(1p) + Chr del(19q)
Oligodendroglioma
temozolomide
Sensitive
:
A2
No biomarker
Glioma
temozolomide
Sensitive
:
A2
No biomarker
Meningioma
bevacizumab + everolimus
Sensitive
:
A2
No biomarker
Meningioma
bevacizumab
Sensitive
:
A2
No biomarker
Meningioma
sunitinib
Sensitive
:
A2
No biomarker
Medulloblastoma
cisplatin + cyclophosphamide + vincristine
Sensitive
:
A2
No biomarker
Medulloblastoma
cisplatin + vincristine + lomustine
Sensitive
:
A2
BRAF V600E
Ganglioglioma
trametinib + dabrafenib
Sensitive
:
A2
No biomarker
Glioma
bevacizumab
Sensitive
:
A2
BRAF V600E
Ganglioglioma
vemurafenib + cobimetinib
Sensitive
:
A2